Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

NCT01313559 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Castrate Resistant Prostate Cancer
Chemotherapy Naive Prostate Cancer
Prostate Cancer

Interventions

DRUG: Pasireotide
DRUG: Everolimus
OTHER: Laboratory biomarker analysis

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Collaborators

[object Object]